Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them
The pharmaceutical and biotechnology industries seem to be stepping up their attempts to secure a carve-out for biopharmaceutical patents from the IPR process. Last week, Jim Greenwood, the president and CEO of BIO and John Castellani, the president…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.